VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Predictors of unsustained MRD negativity in multiple myeloma

In this video, Mattia D’Agostino, MD, University of Turin, European Myeloma Network, Turin, Italy, shares some insights into the importance of measurable residual disease (MRD) as a prognostic tool in multiple myeloma. Dr D’Agostino then highlights predictors of unsustained MRD negativity observed in patients enrolled in the FORTE trial (NCT0220364), including circulating tumor cells (CTCs) and chromosome 1q abnormalities. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter